

## THE VALUE OF Science

Pacific Biomarkers has established a worldwide reputation as a premier laboratory for specialty biomarker testing services supporting drug development. The elite scientists at Pacific Biomarkers have extensive experience and versatile backgrounds that provide the value of scientific expertise from academia, clinical diagnostics,

### Amar A. Sethi, MD, PhD President & Chief Scientific Officer



- Board Certified in Chemical Pathology by the National Board of Health, Denmark, and PhD from University of Copenhagen in Genetics of Cardiovascular Diseases
- Staff physician in Clinical Biochemistry and Cardiology University Hospitals in Denmark. Experience in clinical diagnostics labs in Europe/USA: molecular diagnostic screening for cancer; overseeing hematology, coagulation, immunology. Chair-Elect of Lipids and Vascular Disease Division of AACC

- Extensive research experiences at NHLBI and NIH in atherosclerotic diseases; expertise in cholesterol metabolism, with emphasis on HDL functionality and the development of HDL raising therapies, including synthetic ApoAI-mimetic peptide discoveries

ext. 1700

### Maribeth Raines, PhD Vice President of Laboratory Services



- Biochemist with extensive experience in biomarker development and commercialization, in vitro and clinical diagnostics, especially in Oncology, Inflammation, and Virology
- Experienced in de novo reagent and assay development, technology transfer of immunoassays, molecular diagnostics, flow cytometry, and cell based assays

- Expertise in method standardization, harmonization, and biomarker deployment in emerging markets for support of clinical trials

ext. 1737

### Michael Murphy, PhD, DABCC

Laboratory Director, BD/Strategic Relations



- Board Certified Diplomat of the American Board of Clinical Chemistry (DABCC).
- Extensive experience in the management and direction of technical and scientific organizations in clinical diagnostic, commercial reference, CRO, global central and research laboratories.

- Areas of expertise include: biomarker validation and standardization, quality assurance, laboratory operations, informatics and laboratory automation. Clinical focus areas include diabetes, cardiovascular disease, oncology, infectious and musculoskeletal disease.

ext. 1722

### Candace Adamo, PhD Organ Injury Biomarker Scientist



- Pharmacologist with significant experience in cardiovascular and renal injury
- Experience in immunoassay development, validation of analytical methods, and cell-based assays
- Academic research experience and expertise in cardiology and vascular biology

ext. 1716

### Timothy H. Carlson, PhD, RD, NRCC Senior Consultant



- Board Certified in Clinical Chemistry and Nutrition & Dietetics
- Directed basic and clinical research in the areas of inflammation, hemostasis, lipids and atherosclerosis, bone metabolism, clinical nutrition and clinical laboratory practice
- More than two decades of academic research experience and clinical biochemistry laboratory practice, research and administration

ext. 1728

### Jeff Chamberlain, PhD

Associate Scientist, Business Development



- Degree in bioengineering studying bacterial binding and binding inhibition
- Expertise in biomolecular interaction analysis, including immunoassays and various label-free detection platforms
- Experienced in early-stage technology development and commercialization

ext. 1757

### Elizabeth Teng Leary, PhD, DABCC

Co-founder and Senior Scientific Advisor



- Board Certified Diplomat of the American Board of Clinical Chemistry (DABCC)
- Extensive experience in biomarker assay development, standardization and partnerships with clinical diagnostic manufacturers
- Director of CDC Cholesterol Reference Method Laboratory Network, past Chair of Lipids and Vascular Disease Division of AACC, and past President of NACCCCommercialization